Literature DB >> 21636646

Association of TNFSF15 polymorphism with irritable bowel syndrome.

Marco Zucchelli1, Michael Camilleri2, Anna Nixon Andreasson3,4, Francesca Bresso5, Aldona Dlugosz5, Jonas Halfvarson6, Leif Törkvist7, Peter T Schmidt5, Pontus Karling8, Bodil Ohlsson9, Richard H Duerr10,11, Magnus Simren12, Greger Lindberg5, Lars Agreus3, Paula Carlson2, Alan R Zinsmeister2, Mauro D'Amato1.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder, affecting more than 10% of the general population worldwide. Although a genetic component is suspected, unambiguous susceptibility genes have so far not been identified. This study tested the hypothesis that genes contributing to epithelial barrier integrity, control of mucosal immune responses and interactions with bacteria in the gut are associated with IBS.
METHODS: Single nucleotide polymorphisms (SNPs) corresponding to top signals of association with Crohn's disease at 30 known susceptibility loci were tested for their effect on IBS risk in 1992 individuals from two independent case-control cohorts from Sweden and the USA. Association tests included a conservative Bonferroni correction for multiple comparisons, and were also performed on specific subgroups of patients characterised by constipation (IBS-C), diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBS-A).
RESULTS: The Crohn's disease risk allele rs4263839 G in the TNFSF15 gene was significantly associated with an increased risk of both IBS (p=2.2×10(-5); OR 1.37) and more pronouncedly, IBS-C (p=8.7×10(-7); OR 1.79) in the entire sample. Similar associations and risk effects of the same magnitude were observed in the two cohorts analysed separately. A correlation between rs4263839 genotype and TNFSF15 mRNA expression was detected both in peripheral blood and in rectal mucosal biopsies from healthy individuals (combined p=0.0033).
CONCLUSIONS: TNFSF15 is a susceptibility gene for IBS and IBS constipation. As TL1A, the protein encoded by TNFSF15, contributes to the modulation of inflammatory responses, the results support a role of immune activation in IBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636646      PMCID: PMC3922294          DOI: 10.1136/gut.2011.241877

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  42 in total

1.  Activation of the mucosal immune system in irritable bowel syndrome.

Authors:  Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

Review 2.  Genetic approaches to functional gastrointestinal disorders.

Authors:  Yuri A Saito; Nandita Mitra; Emeran A Mayer
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

3.  Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study.

Authors:  P Aro; J Ronkainen; T Storskrubb; E Bolling-Sternevald; R Carlsson; S E Johansson; M Vieth; M Stolte; L Engstrand; N J Talley; L Agréus
Journal:  Scand J Gastroenterol       Date:  2004-12       Impact factor: 2.423

4.  Mechanisms in IBS: something old, something new, something borrowed...

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2005-06       Impact factor: 3.598

Review 5.  Immunomodulatory properties of substance P: the gastrointestinal system as a model.

Authors:  Hon Wai Koon; Charalabos Pothoulakis
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

6.  Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome.

Authors:  Hans Törnblom; Greger Lindberg; Björn Nyberg; Béla Veress
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 7.  Functional bowel disorders.

Authors:  George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

8.  Increased mast cells in the irritable bowel syndrome.

Authors:  M O'Sullivan; N Clayton; N P Breslin; I Harman; C Bountra; A McLaren; C A O'Morain
Journal:  Neurogastroenterol Motil       Date:  2000-10       Impact factor: 3.598

9.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

Authors:  M P Heyes; K Saito; J S Crowley; L E Davis; M A Demitrack; M Der; L A Dilling; J Elia; M J Kruesi; A Lackner
Journal:  Brain       Date:  1992-10       Impact factor: 13.501

10.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

Authors:  Giovanni Barbara; Vincenzo Stanghellini; Roberto De Giorgio; Cesare Cremon; Graeme S Cottrell; Donatella Santini; Gianandrea Pasquinelli; Antonio M Morselli-Labate; Eileen F Grady; Nigel W Bunnett; Stephen M Collins; Roberto Corinaldesi
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  57 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis.

Authors:  M Camilleri; P Carlson; S McKinzie; M Zucchelli; M D'Amato; I Busciglio; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2011-07-14       Impact factor: 3.598

Review 3.  The microbiome: stress, health and disease.

Authors:  Rachel D Moloney; Lieve Desbonnet; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Mamm Genome       Date:  2013-11-27       Impact factor: 2.957

4.  Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-04-30       Impact factor: 4.052

5.  RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

6.  IBS: A polymorphism in TNFSF15 is associated with susceptibility to IBS.

Authors:  Isobel Franks
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-12       Impact factor: 46.802

Review 7.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 8.  Childhood functional abdominal pain: mechanisms and management.

Authors:  Judith Korterink; Niranga Manjuri Devanarayana; Shaman Rajindrajith; Arine Vlieger; Marc A Benninga
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-10       Impact factor: 46.802

9.  Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Authors:  William V Perks; Ravinder K Singh; Gareth W Jones; Jason P Twohig; Anwen S Williams; Ian R Humphreys; Philip R Taylor; Simon A Jones; Eddie C Y Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

Review 10.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.